Drug Trial Radar · NCT07650916
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
564
Planned (sponsor's estimate)
Start
Jun 25, 2026
Primary completion
Aug 13, 2029
Study completion Aug 13, 2029
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jun 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study compares the efficacy, safety and tolerability of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and adolescents with HIV who are virologically suppressed on anti-retroviral therapy (ART).
Conditions
- HIV
Interventions
CAB ULADrug
CAB ULA will be administered.
RPV ULADrug
RPV ULA will be administered.
CAB LADrug
CAB LA will be administered.
RPV LADrug
RPV LA will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with plasma HIV-RNA greater than or equal to (>=) 50 copies (c)/mL as per Food and Drug Administration (FDA) Snapshot algorithmTime frame: At Month 11
Locations
111 sites in 10 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Phoenix, Arizona · Recruiting
GSK Investigational Site
Bakersfield, California · Recruiting
GSK Investigational Site
Los Angeles, California · Recruiting
GSK Investigational Site
Los Angeles, California · Recruiting
GSK Investigational Site
San Diego, California · Recruiting
GSK Investigational Site
West Hollywood, California · Recruiting
GSK Investigational Site
New Haven, Connecticut · Recruiting
GSK Investigational Site
Washington D.C., District of Columbia · Recruiting
GSK Investigational Site
DeLand, Florida · Recruiting
GSK Investigational Site
Fort Lauderdale, Florida · Recruiting
GSK Investigational Site
Ft. Pierce, Florida · Recruiting
GSK Investigational Site
Jacksonville, Florida · Recruiting
GSK Investigational Site
Miami, Florida · Recruiting
GSK Investigational Site
Orlando, Florida · Recruiting
GSK Investigational Site
Pensacola, Florida · Recruiting
GSK Investigational Site
Vero Beach, Florida · Recruiting
GSK Investigational Site
West Palm Beach, Florida · Recruiting
GSK Investigational Site
West Palm Beach, Florida · Recruiting
GSK Investigational Site
Decatur, Georgia · Recruiting
GSK Investigational Site
Chicago, Illinois · Recruiting
GSK Investigational Site
Baltimore, Maryland · Recruiting
GSK Investigational Site
Grosse Pointe Woods, Michigan · Recruiting
GSK Investigational Site
Kansas City, Missouri · Recruiting
GSK Investigational Site
Las Vegas, Nevada · Recruiting
GSK Investigational Site
Newark, New Jersey · Recruiting
GSK Investigational Site
Santa Fe, New Mexico · Recruiting
GSK Investigational Site
Stony Brook, New York · Recruiting
GSK Investigational Site
Syracuse, New York · Recruiting
GSK Investigational Site
Greensboro, North Carolina · Recruiting
GSK Investigational Site
Winston-Salem, North Carolina · Recruiting
GSK Investigational Site
Columbus, Ohio · Recruiting
GSK Investigational Site
Philadelphia, Pennsylvania · Recruiting
GSK Investigational Site
Pittsburgh, Pennsylvania · Recruiting
GSK Investigational Site
Pittsburgh, Pennsylvania · Recruiting
GSK Investigational Site
Memphis, Tennessee · Recruiting
GSK Investigational Site
Austin, Texas · Recruiting
GSK Investigational Site
Dallas, Texas · Recruiting
GSK Investigational Site
Dallas, Texas · Recruiting
GSK Investigational Site
El Paso, Texas · Recruiting
GSK Investigational Site
Houston, Texas · Recruiting
Showing 40 of 111 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.